Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-t...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

Abetwit Jul. 4 at 1:43 PM

$GUTS picked up a few.

0 · Reply

Morgott438734 Jul. 4 at 10:59 AM

$GUTS looking to add to the position at around $0.2 respectively ! cheers for the heads up !

1 · Reply

ISimplyHaveNoIdea Jul. 4 at 6:03 AM

$GUTS ouch!! Just swung by this one to see where it’s at in relation to its dollar requirements by September. Not looking good in the short term. Thank god @BioRich gave me the heads up. Once this goes through R/S I’m buying BIG!!!

0 · Reply

Donald_J_Dumps Jul. 2 at 11:02 PM

$GUTS i will make sure that this never touches .80 again.

3 · Reply

Morgott438734 Jul. 2 at 7:17 PM

$WEN $BYND $GUTS Meme stock portfolio hit hard this week

1 · Reply

treespider23 Jul. 2 at 3:19 PM

$GUTS holding 4751. And ill keep buying more 😁

2 · Reply

jacksparo Jul. 2 at 1:43 PM

$SLS $IBRX $GUTS $MNKD $OCGN Lets us see where headed in the last trading day of this week ( tomorrow the market will be closed to observe the independent day holiday).

1 · Reply

StockMan3517 Jul. 2 at 12:50 PM

$GUTS cannot wait to see the data next month

0 · Reply

DataJim Jul. 2 at 9:25 AM

$GUTS Definitely thinking of getting in. It’s @BioRich top holding, and I share his interest in $TLSA and $VNDA https://chatgpt.com/share/6a462d86-4cf0-83e8-96e7-c053afb75ba8 I have made my decision after the linked conversation.

2 · Reply

Nik_CA Jul. 1 at 11:12 PM

$GUTS For those who might have missed the latest PT of $4.00 by Craig-Hallum https://ca.investing.com/news/stock-market-news/craighallum-initiates-fractyl-health-stock-coverage-with-buy-rating-93CH-4716411

0 · Reply

Craig-Hallum bullish on Fractyl Health, initiates with a Buy

2026-07-01T11:30:11.000Z - 3 days ago

Fractyl Health initiated with a Buy at Craig-Hallum

Jun 10, 2026, 12:00 PM EDT - 24 days ago

Fractyl Health Transcript: AGM 2026

Jun 4, 2026, 7:00 AM EDT - 4 weeks ago

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

May 14, 2026, 12:20 PM EDT - 7 weeks ago

Fractyl Health Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T21:42:36.000Z - 7 weeks ago

Fractyl Health reports Q1 EPS 6c, consensus (16c)

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Fractyl Health Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Fractyl Health Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Fractyl Health Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 7 weeks ago

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

May 5, 2026, 7:00 AM EDT - 2 months ago

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Fractyl Health Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Fractyl Health Proxy statement: Proxy filing

Mar 24, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Earnings release: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 3 months ago

Fractyl Health Annual report: Q4 2025

2026-03-17T13:50:14.000Z - 3 months ago

H.C. Wainwright says ‘take a breath’ after Fractyl Health selloff

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

2026-02-26T12:36:24.000Z - 4 months ago

Fractyl Health completes randomization in REMAIN-1 cohort

Feb 26, 2026, 7:00 AM EST - 4 months ago

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

2026-02-02T16:50:10.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

Jan 30, 2026, 11:46 AM EST - 5 months ago

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

2026-01-30T16:10:26.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

2026-01-30T14:50:16.000Z - 5 months ago

Fractyl Health price target lowered to $2 from $5 at BofA

2026-01-29T21:26:44.000Z - 5 months ago

Fractyl Health downgraded to Equal Weight from Overweight at Morgan Stanley

Jan 29, 2026, 8:00 AM EST - 5 months ago

Fractyl Health Transcript: Study result

Jan 29, 2026, 8:00 AM EST - 5 months ago

Fractyl Health Press release: Study result

Jan 29, 2026, 8:00 AM EST - 5 months ago

Fractyl Health Slides: Study result

2026-01-29T12:21:38.000Z - 5 months ago

Fractyl Health announces results from trial evaluating Revita

Jan 29, 2026, 7:00 AM EST - 5 months ago

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

2026-01-27T17:16:01.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

2026-01-08T12:42:27.000Z - 6 months ago

Fractyl Health price target lowered to $8 from $10 at Morgan Stanley

2026-01-06T12:10:45.000Z - 6 months ago

Fractyl Health appoints Lara Smith Weber as CFO

Jan 6, 2026, 7:00 AM EST - 6 months ago

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

2026-01-05T12:21:09.000Z - 6 months ago

Fractyl Health outlines strategic outlook for 2026

Jan 5, 2026, 7:00 AM EST - 6 months ago

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

Dec 15, 2025, 5:45 PM EST - 7 months ago

Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones

2025-12-10T21:21:05.000Z - 7 months ago

Fractyl Health management to meet virtually with Needham

2025-12-05T17:20:11.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

PLRZ

2025-12-04T17:10:59.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

PLRZ SMMT

Dec 3, 2025, 1:45 PM EST - 7 months ago

Fractyl Health Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-02T12:05:59.000Z - 7 months ago

Fractyl Health announces 6-month results from REVEAL-1 Cohort

Dec 2, 2025, 7:00 AM EST - 7 months ago

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Dec 1, 2025, 7:00 AM EST - 7 months ago

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:30 PM EST - 8 months ago

Fractyl Health Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Fractyl Health Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Fractyl Health Earnings release: Q3 2025

Nov 12, 2025, 4:05 PM EST - 8 months ago

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Nov 5, 2025, 7:00 AM EST - 8 months ago

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

Oct 7, 2025, 7:00 AM EDT - 9 months ago

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Sep 26, 2025, 8:00 AM EDT - 10 months ago

Fractyl Health Transcript: Study Update

Sep 26, 2025, 8:00 AM EDT - 10 months ago

Fractyl Health Press release: Study Update

Sep 26, 2025, 8:00 AM EDT - 10 months ago

Fractyl Health Slides: Study Update

Sep 26, 2025, 7:41 AM EDT - 10 months ago

Fractyl Health says experimental procedure helps maintain weight-loss in study

Sep 26, 2025, 7:05 AM EDT - 10 months ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sep 26, 2025, 7:00 AM EDT - 10 months ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Sep 26, 2025, 7:00 AM EDT - 10 months ago

Fractyl Health Slides: Corporate Presentation

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 25, 2025, 8:00 AM EDT - 11 months ago

Fractyl Health Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

Fractyl Health Proxy statement: Proxy Filing

Aug 13, 2025, 11:30 AM EDT - 11 months ago

Fractyl Health Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Fractyl Health Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Fractyl Health Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Fractyl Health Earnings release: Q2 2025

Aug 12, 2025, 4:05 PM EDT - 11 months ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 11 months ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 11 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jun 23, 2025, 7:40 AM EDT - 1 year ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 1 year ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 1 year ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health Quarterly report: Q1 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Proxy statement: Proxy Filing

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Fractyl Health Registration statement: Registration Filing

Mar 3, 2025, 4:30 PM EST - 1 year ago

Fractyl Health Earnings Call Transcript: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Fractyl Health Earnings release: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Fractyl Health Annual report: Q4 2024

Mar 3, 2025, 4:05 PM EST - 1 year ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 3, 2025, 7:00 AM EST - 1 year ago

Fractyl Health Registration statement: Registration Filing

Feb 24, 2025, 7:00 AM EST - 1 year ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 1 year ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 1 year ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 4, 2024, 1:30 PM EST - 1 year ago

Fractyl Health Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 12, 2024, 4:30 PM EST - 1 year ago

Fractyl Health Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Fractyl Health Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Fractyl Health Quarterly report: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 1 year ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Oct 1, 2024, 9:00 AM EDT - 1 year ago

Fractyl Health Transcript: Chardan's 8th Annual Genetic Medicines Conference

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Abetwit Jul. 4 at 1:43 PM

$GUTS picked up a few.

0 · Reply

Morgott438734 Jul. 4 at 10:59 AM

$GUTS looking to add to the position at around $0.2 respectively ! cheers for the heads up !

1 · Reply

ISimplyHaveNoIdea Jul. 4 at 6:03 AM

0 · Reply

Donald_J_Dumps Jul. 2 at 11:02 PM

$GUTS i will make sure that this never touches .80 again.

3 · Reply

Morgott438734 Jul. 2 at 7:17 PM

$WEN $BYND $GUTS Meme stock portfolio hit hard this week

1 · Reply

treespider23 Jul. 2 at 3:19 PM

$GUTS holding 4751. And ill keep buying more 😁

2 · Reply

jacksparo Jul. 2 at 1:43 PM

$SLS $IBRX $GUTS $MNKD $OCGN Lets us see where headed in the last trading day of this week ( tomorrow the market will be closed to observe the independent day holiday).

1 · Reply

StockMan3517 Jul. 2 at 12:50 PM

$GUTS cannot wait to see the data next month

0 · Reply

DataJim Jul. 2 at 9:25 AM

2 · Reply

Nik_CA Jul. 1 at 11:12 PM

0 · Reply

MarketsParadise Jul. 1 at 8:16 PM

Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $ALZN $GUTS $AURE $MMA ..33

0 · Reply

BioRich Jul. 1 at 4:35 PM

$GUTS @Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) $ABVX 3) $IBRX 4) $ALT 5) $KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

3 · Reply

bizness1957 Jul. 1 at 12:50 PM

$GUTS https://www.streetinsider.com/dr/news.php?id=26716847&gfv=1

0 · Reply

DSAdsdsas Jul. 1 at 12:27 AM

$GUTS GLP-1 drugs manage obesity by suppressing appetite. Revita aims to address one of the underlying causes by restoring duodenal function damaged by years of ultra-processed foods. If successful, that’s a fundamentally different value proposition: restoring physiology instead of relying on lifelong pharmacological appetite suppression.

0 · Reply

Ritschier Jun. 30 at 11:53 PM

$GUTS If the data for Revita come in good, it's hard to beat. Pill or no pill. That's how I interpret the screenshot. ;-) Both Revita and Rejuva have groundbreaking potential. Under retail radar? If it were pills, it would be a much more popular bet, I guess. But, like I mentioned before, I don't mind GUTS not winning the popular vote. I like the current setup.

1 · Reply

Sunnibouno Jun. 30 at 7:15 PM

$GUTS

0 · Reply

Thalassophile Jun. 30 at 2:43 PM

$GUTS

0 · Reply

JuggernautRaider Jun. 29 at 6:17 PM

$GUTS Fractyl? How has this 💩 not gotten flushed yet 😆

1 · Reply

stocktwit162 Jun. 29 at 3:22 PM

$GUTS $SLS please could someone do a welfare check on my friend @LegalTendies ? he also goes by the name @BioRich

1 · Reply

Striving2bmore Jun. 29 at 2:56 PM

$GUTS

0 · Reply

StockMan3517 Jun. 28 at 11:22 PM

$GUTS what’s the bear case here? I don’t see one but I’m all ears if anyone has one

2 · Reply

Evie47 Jun. 27 at 11:04 PM

$SLS Don't forget, if you listened to @BioRich at the start of the year he would have told you to invest in $GUTS which is down 65.91% ytd and told people to not invest in SLS which is up 174.83% on the year. Guys is certifiable idiot.

3 · Reply

Market Cap	120.89M
Revenue (ttm)	0.00
Net Income (ttm)	-140.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.41

Volume	842,400
Avg Vol	1,949,990
Day's Range	N/A - N/A
Shares Out	158.65M
Stochastic %K	15%
Beta	2.29
Analysts	Strong Sell
Price Target	$5.03